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Normal endometrial function requires a balance of progesterone
(P4) and estrogen (E2) effects. An imbalance caused by increased
E2 action and/or decreased P4 action can result in abnormal endo-
metrial proliferation and, ultimately, endometrial adenocarcinoma,
the fourth most common cancer in women. We have identified
mitogen-inducible gene 6 (Mig-6) as a downstream target of proges-
terone receptor (PR) and steroid receptor coactivator (SRC-1) action in
the uterus. Here, we demonstrate that absence of Mig-6 in mice
results in the inability of P4 to inhibit E2-induced uterine weight gain
and E2-responsive target genes expression. At 5 months of age, the
absence of Mig-6 results in endometrial hyperplasia. Ovariectomized
Mig-6d/d mice exhibit this hyperplastic phenotype in the presence of
E2 and P4 but not without ovarian hormone. Ovariectomized Mig-6d/d
micetreatedwithE2developedinvasiveendometrioid-typeendometrial
adenocarcinoma. Importantly, the observation that endometrial carci-
nomas from women have a significant reduction in MIG-6 expression
providescompellingsupport foran importantgrowthregulatoryrole for
Mig-6 in the uterus of both humans and mice. This demonstrates the
Mig-6 is a critical regulator of the response of the endometrium to E2 in
regulating tissue homeostasis. Since Mig-6 is regulated by both PR and
SRC-1, this identifiesaPR,SRC-1,Mig-6 regulatorypathwaythat is critical
in the suppression of endometrial cancer.
estrogen  endometrial cancer  progesterone  progesterone receptor  SRC-1
The ovarian steroid hormones progesterone (P4) and estrogen(E2) are essential regulators of reproductive events associated
with all aspects involved in the establishment and maintenance of
pregnancy (1, 2). P4 and E2 function both synergistically and
antagonistically to regulate appropriate uterine function by acting
through their cognate nuclear receptors to coordinate uterine
epithelial–stromal communication in the regulation of endometrial
cell proliferation and differentiation. An imbalance caused by
increased E2 action and/or decreased P4 action can result in abnormal
endometrial proliferation and endometrial adenocarcinoma. Endome-
trial cancer is the most common gynecological cancer in the United
States (3). Endometrioid-type endometrial adenocarcinoma and its
precursor lesion, endometrial hyperplasia, are associated with unop-
posed estrogen exposure (4, 5). Elucidating the molecular mecha-
nisms by which the steroid hormones control uterine physiology is
important to understanding the pathology of these diseases.
The action of the steroid hormone receptors are modulated in
part by members of the p160 family of steroid receptor coactivators
(SRCs). The SRCs facilitate steroid hormone receptor regulation
of gene transcription by executing a diverse number of processes
including chromatin remodeling, RNA processing, and receptor
degradation (6). The SRC family is composed of 3 distinct but
functionally and structurally related members: SRC-1/NcoA1 (7),
SRC-2/TIF2/GRIP1 (8), and SRC-3/RAC3/ACTR/pCIP/AIB1/
TRAM1 (9). The SRC family members enhance the transcriptional
activity of a variety of nuclear receptors, including estrogen receptor
 (ER, also known as ESR1), estrogen receptor  (ER, also
known as ESR2), glucocorticoid receptor (GR), and progesterone
receptor (PR) (10–12) and are expressed in a variety of hormone-
responsive tissues including the uterus, brain, prostate, liver, and
breast (7, 13–15). Although female SRC-1/ mice are fertile,
reduced steroid sensitivity in the uterus of SRC-1/ mice is
demonstrated by a reduction in the ability of the endometrial
stroma cells to undergo a decidual transformation (7). This phe-
notype indicates that these coregulators may play a necessary role
in coordinating steroid hormone regulation of normal reproductive
uterine function. Using high-density DNA microarray technology,
we have identified Mig-6 as a gene whose regulation by P4 is
dependent upon SRC-1.
Mig-6 is an immediate early response gene that can be induced
by various mitogens and commonly occurring chronic stress stimuli
(16–18). Mig-6 is an adaptor molecule containing a CRIB domain,
a src homology 3 (SH3) binding domain, a 14–3-3 binding domain,
and an epidermal growth factor receptor (EGFR) binding domain
(19, 20). Sustained Mig-6 expression is thought to trigger cells to
initiate hypertrophy in chronic pathological conditions, such as
diabetes and hypertension (21, 22). Ablation of Mig-6 in mice has
led to the development of animals with epithelial hyperplasia,
adenoma, and adenocarcinomas in organs, such as the lung, gall-
bladder, and bile duct (23, 24). Mig-6 is located on human chro-
mosome 1p36, a locus frequently associated with human cancer (25,
26). Decreased expression of Mig-6 is observed in human breast
carcinomas that correlate with reduced overall survival of breast
cancer patients (27, 28). Mig-6 is mutated in human non-small-cell
lung cancer (NSCLC) cell lines NCI-H226 and NCI-H 322M and in
one primary human lung cancer (24). Recently, altered Mig-6
expression has been observed in endometrial RNA taken from
women with endometriosis (29). These data point to Mig-6 as a
tumor suppressor gene in both mice and humans. However, the
function of Mig-6 in reproductive biology has remained elusive.
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In this study, we used conditional ablation of Mig-6 in mice to
demonstrate that Mig-6 is an important molecule in uterine
physiology in part by regulating the ability of P4 to attenuate E2
signaling. These mice develop endometrial hyperplasia within 5
months, and, if exposed to exogenous E2 for 3 months, develop
invasive type I endometrial adenocarcinoma. Analysis of Mig-6
in the human endometrium shows that the expression of Mig-6
is decreased in human endometrial cancers. Thus, these results
demonstrate the importance of Mig-6 in steroid hormone reg-
ulation and human endometrial cancer.
Results
Identification of P4 and SRC-1 Regulated Genes Using Microarray
Analysis. The impact of SRC-1 ablation on uterine mRNA expres-
sion profiles in response to P4 was examined by isolating RNA from
ovariectomized SRC-1/ and wild-type mice that were treated
with either vehicle (sesame oil) or P4 (1 mg) for 4 h (n  9 per
genotype per treatment). The experimental design not only allowed
for the effect of SRC-1 in SRC-1/ mice to be determined, but also
afforded the comparison of the effect of vehicle and P4 on wild-type
and SRC-1/ mice. Using this experimental design, the identifi-
cation of differentially expressed genes was derived from 3 physi-
ologically relevant comparisons (Fig. S1A). The summary of the
number of differentially expressed genes for the 3 comparisons is
shown in supporting information (SI) Table S1. Comparison 1
identified genes differentially expressed between wild-type and
SRC-1/ mice in the absence of P4 treatment. Comparison 2
identified genes regulated by SRC-1 in the presence of P4, and
comparison 3 identified P4 responsive genes in wild-type mice. A
complete list of the increased and decreased genes that are iden-
tified as significant for comparisons 1–3 are presented in Table S2.
To identify the impact of SRC-1 ablation on P4 induction of gene
expression, we identified genes that overlapped between compar-
isons 2 and 3. (Fig. S1B) graphically shows the overlap in the analysis
of SRC-1-dependent P4 responsive genes (comparison 2) and P4
responsive genes (comparison 3). We identified 5 targets of which
the mRNA expression was induced by P4 in wild-type mice but not
in SRC-1/ mice (Fig. S1C). These genes were Mig-6, Myc, Il13ra2,
and an EST. The EST was not analyzed further because it did not
have any known homologous gene and its expression was not
PR-dependent, based on our previous microarray data (30).
To confirm whether the gene regulatory effects of P4 are
mediated through SRC-1 and PR, we ovariectomized SRC-1/
mice, progesterone receptor knockout (PRKO), and WT mice.
After P4 treatment for 4 h, the uteri were collected, RNA was
prepared, and total RNA was analyzed by real time RT-PCR.
Expression of all 3 genes was highly induced by P4 in the wild-type
mice, but induction was significantly decreased in the SRC-1/
mice (Fig. S1D). The P4 induction was also not detected in the
PRKO mice. Therefore, real time RT-PCR confirmed the results
of the microarray analysis and further showed that their expression
was PR dependent.
Ablation of Mig-6 in mice leads to animals with epithelial
hyperplasia, adenoma, and adenocarcinoma in organs like the lung,
gallbladder, and bile duct (24). This tumor suppressor function in
mice (23, 24) is also observed in humans (25, 26). The fact that Mig-6
was found to be a SRC-1-dependent PR-responsive gene prompted
us to investigate its function in the murine endometrium. The
spatial expression of Mig-6 was examined by in situ hybridization
(Fig. S2). Mig-6 transcripts were undetectable in the vehicle-treated
uterus. However, Mig-6 mRNAs were strongly expressed in the
stroma, luminal epithelium, and glandular epithelium by P4 treat-
ment. In contrast, these mRNAs were significantly decreased in the
uteri of ovariectomized SRC-1/ and PRKO mice receiving P4
treatment. These results demonstrate that Mig-6 is PR and SRC-1
dependently regulated in all compartments of the endometrium
including the epithelium and stroma but not myometrium.
The Epithelial Hyperplastic Effect in Mice with Conditional Mig-6
Ablation in the Uterus. Since Mig-6 ablation results in numerous
pathologies and decreased longevity (23, 24, 31, 32), our ability to
investigate the role of Mig-6 in the mouse uterus is severely limited.
To effectively investigate the role of Mig-6 in the regulation of
uterine function and the response to hormonal stimulation, we
generated a Mig-6 conditional null allele, the Mig-6 flox allele
(Mig-6f/f) (33). Mig-6f/f mice were bred to PRCre (34) mice to generate
conditional Mig-6 ablation (PRcre/Mig-6f/f; Mig-6d/d) in the repro-
ductive tract. Significant morphological differences in the uteri of
Mig-6d/d and Mig-6f/f were not observed at 2 months of age.
However, analysis of Mig-6d/d uteri compared to Mig-6f/f mice at 5
months of age (n  10) showed a significant increase in wet weight
(Fig. 1 A and B). Histological analysis of these uteri showed an
increase in the number of endometrial glands and in the gland/
stroma ratio in the uterus of Mig-6d/d mice (Fig. 1 C–H); however,
the myometrium was not enlarged. These histological changes
demonstrate that the uterus of the Mig-6d/d mouse displays endo-
metrial hyperplasia, a predisposing factor to endometrial adeno-
carcinoma in humans.
To determine if the endometrial epithelial hyperplasia in the
Mig-6d/d mice is caused by alterations of ER signaling, cell prolif-
eration, and/or apoptosis, we performed immunohistochemical
staining for ER, Ser 118 phospho-ER, phosphohistone H3, and
caspase 3. Immunohistochemical staining of caspase 3 was un-
changed in the luminal or glandular epithelium of nonpregnant
Mig-6d/d mice compared to wild-type control mice (data not shown).
However, immunohistochemical staining of phosphohistone H3
showed that the endometrial glandular cells exhibited a significant
increase in proliferation in the Mig-6d/d mice (Fig. 1D). Supportive
of E2 being the cause of the increase in epithelial proliferation, ER
and phosphorylation of ER at Ser 118 were also significantly
increased in the endometrial glands (Fig. 1 F and H).
Steroid Hormone Regulation of Mig-6 in the Murine Uterus. To
determine if the uteri of Mig-6d/d exhibited an altered response
to steroid hormones, Mig-6d/d and Mig-6f/f mice were ovariecto-
mized and treated with vehicle, E2, P4, or E2  P4 daily for 3
days and killed 6 h after the last injection (n  5 per genotype
Fig. 1. The hyperplastic effect of conditional Mig-6 ablation in the murine
uterus. (A) Uteri of 5-month-old PRcre/Mig-6f/f (Mig-6d/d) and Mig-6f/f mice. (B)
Quantitative weights of uteri in Mig-6d/d and Mig-6f/f mice. The results repre-
sent the mean  SEM of 5 animals. **, P  0.01, unpaired t test. (C–H)
Immunohistochemical analysis of ER (C and D), phospho-ER (E and F), and
phosphohistone H3 (G and H) in uteri of 5-month-old Mig-6f/f (C, E, and G) and
Mig-6d/d (D, F, and H) mice.
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per treatment). Mig-6d/d and Mig-6f/f uteri showed no difference
in weight gain or expression of PR, ER, or their respective
target genes when the mice were treated with vehicle, E2, or P4.
However, Mig-6d/d mice treated with E2  P4 showed a signif-
icant increase in uterine weight (Fig. 2A), vascularization (Fig.
2B), and expression of endometrial epithelial ER target genes,
Ltf (lactotransferrin), Clca3 (chloride channel calcium activated
3), and C3 (complement component 3), (Fig. 2C) compared to
E2  P4-treated Mig-6f/f uteri. The expression of 2 endometrial
epithelial PR target genes, Fst (follistatin) and Areg (amphiregu-
lin), is not changed in the Mig-6d/d mice in response to E2  P4
treatment (Fig. 2D). However, the expression of PR mRNA is
Fig. 2. Steroid hormone regulation of Mig-6 in the murine uterus. (A) The ratio of uterine weight to body weight in Mig-6d/d and Mig-6f/f mice treated with
E2, P4, or E2 plus P4 for 3 days. (B) Uteri of Mig-6d/d and Mig-6f/f mice treated with E2 plus P4 for 3 days. (C) ER-regulated gene expression in uteri of Mig-6d/d
and Mig-6f/f mice treated with E2 plus P4. Real-time RT-PCR analysis of Ltf, Clca3, and C3 was performed. (D) PR and PR-regulated gene expression in uteri of
Mig-6d/d and Mig-6f/f mice treated with E2 plus P4. Real-time RT-PCR analysis of PR, Fst, and Areg was performed. (E) Immunohistochemical analysis of PR in uteri
of Mig-6d/d and Mig-6f/f mice treated with E2 plus P4. (F) Quantification of PR positive cells in stroma of Mig-6d/d and Mig-6f/f mice. The results represent the mean 
SEM. ***, P  0.001.
Fig. 3. Steroid hormone-dependent formation of
endometrial cancer in Mig-6d/d mice. (A) Uteri of
5-month-old ovariectomized Mig-6d/d and Mig-6f/f
mice treated with vehicle. H&E stained section show-
ing normal uterus in the ovariectomized Mig-6d/d and
Mig-6f/f mice. (B) Formation of endometrial cancer in
ovariectomized Mig-6d/d mice treated with E2. Endo-
metrial cancer induced in the uteri of ovariectomized
Mig-6d/d mice treated with E2 for 3 months. H&E
stained section showing simple hyperplasia in the Mig-
6f/f mice and endometrioid endometrial cancer in the
Mig-6d/d mice. (C) Uteri of 5-month-old ovariectomized
Mig-6d/d and Mig-6f/f mice treated with E2  P4 for 3
months. H&E stained section showing hyperplasia
uterus in the ovariectomized Mig-6d/d mice treated
with E2  P4 for 3 months.











significantly decreased in the Mig-6d/d mice compared to that of
Mig-6f/f mice. Immunohistochemical analysis of PR expression in
the Mig-6d/d mice shows that epithelial PR expression is normal
but the expression of PR in the endometrial stroma cells is
significantly reduced (Fig. 2 E and F). Since P4 attenuates E2
regulation of proliferation and gene expression by regulating the
expression of a yet-to-be-identified paracrine signal from the
stromal cells to the epithelial cells, the regulation of the expres-
sion of PR in the endometrial stromal cells by Mig-6 is critical for
the ability of P4 to attenuate the E2-regulated uterine weight
gain, vascularization, and expression of ER target genes.
To assess the role of Mig-6 in uterine function, female Mig-6d/d
mice were mated to wild-type male mice for 6 months. Mig-6d/d mice
were completely infertile (Table S3). Since the PRCre mouse shows
Cre recombinase activity in the pituitary, ovary, uterus, and mam-
mary gland, the cause of infertility in these mice may be the result
of a defect in any of these tissues (34). To test for an ovarian
phenotype, female Mig-6f/f and Mig-6d/d mice were examined for
their ability to ovulate normally in response to a superovulatory
regimen of gonadotropins. Mig-6f/f and Mig-6d/d yielded 24.75  6.61
and 24.83  7.88 oocytes, respectively. Also, Mig-6f/f and Mig-6d/d
mice did not show any alterations in ovarian morphology and
exhibited a normal estrus cycle (data not shown). Finally, cycling
female Mig-6f/f and Mig-6d/d mice exhibited normal levels of serum
P4 and E2 at 2 and 5 months of age (data not shown). These results
show that ovarian morphology, steroidogenesis, and function were
not affected in the Mig-6d/d females. These data suggest that the
defects observed in the Mig-6d/d mice are inherent to the uterus.
Thus, to determine if the infertility was in part because of loss of the
ability of the uterus to support implantation, we investigated the
ability of the uterus to undergo a decidual reaction. Ovariectomized
female Mig-6f/f and Mig-6d/d mice (n  3) were treated with
hormones and the uterus was mechanically stimulated to mimic the
signaling of the embryo at implantation and to induce decidual-
ization. Gross anatomy of the decidual and control horn showed an
increase in size for Mig-6d/d mice compared to the Mig-6f/f mice (Fig.
S3). However, the ratio of stimulated-to-unstimulated horn weight
was not changed in the Mig-6f/f and Mig-6d/d mice. These results
suggest that ablation of Mig-6 in PR-expressing cells alters murine
fertility because of dysregulation of E2 and P4 but not because of
defects in ovarian or uterine function.
Tumor Suppressor Function of Mig-6 in the Uterus. As endometrial
hyperplasia is an immediate precursor to endometrioid-type endo-
metrial carcinoma, the hyperplastic phenotype in the Mig-6d/d mice
suggests that Mig-6 has a tumor suppressor role in the tumorigenesis
of endometrial cancer. We examined the role of ovarian steroid
hormones in the development of the hyperplastic phenotype in
Mig-6d/d mice. Six-week-old Mig-6f/f and Mig-6d/d mice were ovari-
ectomized and treated with vehicle, E2, or E2  P4 and killed at 5
months of age (n  10 per genotype per treatment). Ovariecto-
mized Mig-6d/d mice did not develop endometrial hyperplasia as
observed in intact Mig-6d/d mice (Fig. 3A). This demonstrates that
the endometrial hyperplasia phenotype of Mig-6d/d mice is depen-
dent on ovarian hormone stimulation.
Mig-6d/d mice treated with E2 for 3 months showed a significant
increase in uterine weight compared to Mig-6f/f mice (Fig. 3B).
Although the Mig-6f/f mice showed endometrial hyperplasia as
expected from chronic E2 treatment, they did not show the
pathology observed in the uteri of intact Mig-6d/d mice or Mig-6d/d
mice treated with E2. All of the Mig-6d/d mice treated with E2
developed invasive endometrioid-type endometrial adenocarci-
noma. The neoplastic endometrial glands in the Mig-6d/d mice
invaded through the uterine muscle wall and invaded adjacent
structures such as the colon, pancreas, and skeletal muscle. This
result demonstrates that Mig-6 may have an estrogen-dependent
tumor suppressor function in endometrial cancer. Finally, ovariec-
tomized Mig-6d/d mice treated with E2  P4 for 3 months showed
a significant increase in uterine wet weight and developed endo-
metrial hyperplasia (Fig. 3C) but not the endometrial carcinoma
observed in the E2-treated mice. Therefore, P4 treatment was able
to attenuate the pathology observed in the Mig-6d/d mice after E2
treatment but not completely block the endometrial hyperplasia.
These results demonstrate that Mig-6 is important to regulate the
response of the uterus to E2 stimulation in part by mediating the
protective action of P4. However, Mig-6 also regulates other path-
ways independent of P4 that control endometrial cell proliferation.
Downregulation of MIG-6 in Human Endometrial Cancer. Mig-6 abla-
tion shows altered uterine function because of the inability of P4 to
attenuate E2 action, which is a common characteristic of endome-
trial dysfunction in humans (35, 36). The expression of Mig-6 in the
human endometrium during the menstrual cycle was determined by
real-time quantitative PCR and immunohistochemistry. The ex-
pression of Mig-6 was highest in the early secretory phase of the
cycle (Fig. 4A) and this increase in expression was the result of an
increase in the expression of Mig-6 in the endometrial epithelium
(Fig. 4B). The increase in expression of Mig-6 during this phase of
the cycle correlates with P4 regulation as observed in the mouse.
We investigated the expression of MIG-6 in endometrial biopsies
from patients with endometrioid carcinoma (n  10) and normal
endometrium (n  5). The level of MIG-6 mRNA is significantly
decreased in patients with endometrioid carcinoma (32.8%) compared
to endometrial biopsies taken from normal women during the secretory
phase of the cycle. (Fig. 4C). Immunohistochemical analysis also
shows a decrease in the protein level of MIG-6 in patients with
endometrial cancer compared to normal women (Fig. 4D).
Discussion
P4, acting through its nuclear receptors, plays important roles in
uterine functions associated with the establishment and mainte-
nance of pregnancy (37, 38). The identification of P4-regulated
pathways in the uterus is thus crucial for understanding the
impairments that underlie disruption of steroid hormone control of
uterine cell proliferation and differentiation. In previous studies, we
have identified P4-regulated genes using microarray analysis on
P4-treated PRKO uteri (30). We have identified Mig-6 as a target
of SRC-1 and PR in the uterus.
Fig. 4. Expression of MIG-6 in endometrial tissue from healthy women and
from women with endometrioid endometrial cancer. (A) The expression of
MIG-6 in the human endometrium during the menstrual cycle. Real-time
RT-PCR analysis of MIG-6 was performed on human endometrium during the
menstrual cycle. (B) Immunohistochemistry analysis of MIG-6 was performed
in the human endometrium during the menstrual cycle. (C) Real-time RT-PCR
analysis of Mig-6 was performed on total RNA obtained from women with
endometrioid carcinoma. (D) Immunohistochemical analysis of MIG-6 was
performed on endometrium obtained from women with endometrioid car-
cinoma. The results of real-time RT-PCR represent the mean  SEM. *, P  0.05.
8680  www.pnas.orgcgidoi10.1073pnas.0903632106 Jeong et al.
Ablation of Mig-6 in mice results in a 50% reduction of the
Mig-6/ litter size for an unidentified reason (31, 33). The 50% of
the Mig-6/ mice that escape the lethal phenotype, develop joint
deformities, and the majority of mice die within 6 months. These
mice also develop neoplasias of the lungs and skin (23, 31). The
embryonic lethality and multitissue carcinogenesis makes it difficult
to investigate the impact of ablation of Mig-6 in uterine biology. To
effectively investigate the role of Mig-6 in the uterus, we generated
a Mig-6 conditional null allele by introducing LoxP sites (33). The
uterine histology of Mig-6d/d mice demonstrate epithelial hyperpla-
sia similar to the 9-month-old survival Mig-6/ mouse (33). This
hyperplastic phenotype of Mig-6d/d and Mig-6/ supports the tumor
suppressor role of Mig-6 in the tumorigenesis of endometrial cancer.
Mig-6 mediates the ability of P4 to regulate E2-dependent uterine
weight gain. Normally, E2 stimulates uterine growth and epithelial
cell proliferation (39). P4 antagonizes E2 actions, such as the
stimulation of proliferation of the epithelial cells in the mouse
uterus (40). Mig-6d/d and Mig-6f/f mice both respond to E2 treatment
with an increase in uterine wet weight. This indicates that ablation
of Mig-6 does not enhance the effect of E2 treatment alone. When
we examined the ability of P4 to inhibit E2-induced uterine hyper-
trophy, P4 did not inhibit the E2-induced hypertrophy in Mig-6d/d
mice (Fig. 2). In a separate experiment, we treated wild type,
PRcre/, Mig-6f/f, and Mig-6d/d with E2 and P4 for 3 days and
measured uterine weight gain. As expected, the response of PRcre/,
Mig-6f/f, and wild-type mice was similar with P4 dampening the
E2-induced uterine hypertrophy. The Mig-6d/d mice again demon-
strated an increase in uterine weight gain in the presence of P4 and
E2. These results demonstrate that Mig-6 mediates the ability of P4
to regulate E2-dependent uterine weight gain. Examination of
endometrial epithelial P4 target gene expression showed no change
in the ability of PR to regulate the expression of Fst and Areg in the
Mig-6d/d mouse. Interestingly, the expression of PR mRNA is
significantly decreased in the Mig-6d/d mice compared to that of
Mig-6f/f (Fig. 2). Immunohistochemical analysis of PR expression in
the Mig-6d/d mice showed that epithelial PR expression is not altered
but that PR expression in the endometrial stroma cells is signifi-
cantly reduced. P4 attenuates E2 regulation of proliferation and
gene expression by regulating the expression of a yet-to-be-
identified paracrine signal from the stromal cells to the epithelial
cells (41, 42). However, the increase in ER target gene expression
at 8 weeks of age was not the result of a change in ER or
coactivator level (data not shown). Interestingly, there is an increase
in ER levels at 5 months of age with the epithelial hyperplastic
phenotype, but its impact on gene expression at this time remains
unknown. Nonetheless, we have gained valuable insight into steroid
hormone regulation in the uterus and Mig-6’s role in that regulation.
In addition, we have shown that MIG-6 is expressed in the
human endometrium in a cycle-dependent manner that cor-
relates with its being under the control of P4 as observed in the
mouse. We have also demonstrated that its expression is
decreased in endometrioid carcinoma when compared to
expression in normal endometrium during the secretory phase.
Since the endometriod carcinoma samples assayed were ac-
quired from postmenopausal women, the decrease in MIG-6
expression may be a result of the hormonal status of post-
menopausal women. Endometrial diseases such as endometrial
cancer and endometriosis are known to be hormone-related
malignancies. Exposure to E2 is one of the endocrine risk
factors for developing endometrial cancer and endometriosis
(35), and a lower incidence of these diseases is noted in women
with decreased endogenous E2 production. In contrast, P4
exposure is a negative risk factor for these disease (43), and
pregnancy or progestin-based therapies can lead to disease
regression in some women (44). Since endometrial cancer is a
disease most often found in postmenopausal women, the lower
levels of progesterone in these women may result in a lack of
induction of MIG-6 that may be required to regulate endo-
metrial epithelial proliferations. Recently, published microar-
ray gene expression profiles of the endometrium of women
with or without endometriosis showed that a number of P4
target genes incluing MIG-6 were dysregulated during the
window of implantation, at which time the endometrium is
exposed to the highest levels of P4 (29, 45). Mig-6d/d mice
developed endometrial adenocarcinoma with E2 but not with
E2  P4. Thus, progesterone acting through the PR may be
beneficial for controlling endometrial cancer by inducing
Mig-6 expression. The Mig-6d/d mice treated with E2  P4 still
develop endometrial hyperplasia, which suggests that Mig-6 is
a critical factor involved in P4 protection against the devel-
opment of endometrial cancer. However, the ability of P4 to
prevent E2-induced endometrial adenocarcinoma despite the
absence of Mig-6 and the reduction in PR levels in the stroma
implicates additional mechanisms of protection. Furthermore,
the development of E2-induced endometrial adenocarcinoma
in Mig-6d/d mice suggests that Mig-6 has an important role as
a negative regulator of E2-induced tumorigenesis. However, it
is not only the expression of MIG-6 that has been shown to be
altered in cancer. In addition, the MIG-6 gene has been shown
to be mutated in the human NSCLC cell lines NCI-H226 and
NCI-H 322M, and in 1 primary human lung cancer (24). Thus,
when examining cases of P4 resistance in endometrial cancer,
aside from examining MIG-6 expression levels, endometrial
carcinoma samples should also be assayed for mutations in
MIG-6 as these mutations may be as detrimental as loss of
MIG-6 expression. Regardless, the molecular mechanism by
which loss of MIG-6 function, either by loss of expression or
mutations in the MIG-6 gene, regulates endometrial cancer
needs to be addressed. Further dissection of the intricacies of
these pathways will lend important insight into the mecha-
nisms that regulate endometrial tumorigenesis.
In summation, Mig-6 ablation results in increased ER activity
in the presence of P4, which normally antagonizes ER activity.
In humans, we have shown that the expression of MIG-6 is
decreased in human endometrial endometrioid carcinoma. Our
findings demonstrate that Mig-6 is a novel mediator of steroid
hormone signaling in the uterus. Endometrial cancer is a uterine
disease in which hormonal regulation is perturbed. The altered
expression of MIG-6 in endometrial cancer may serve as a
possible cause of these pathologies. Mice with conditional
ablation of Mig-6 in the uterus provide a more faithful model for
human endometrial cancer with respect to pathology and hor-
mone sensitivity than any previous models. This model is useful
for finding new targets for the diagnosis and treatment of
endometrial cancer. Determining how Mig-6 mediates this action
will be critical in understanding the role of steroid hormone
signaling in endometrial function and dysfunction and in devel-
oping therapy for both uterine diseases.
Materials and Methods
Animals and Hormone Treatments. Mice were maintained in the designated
animal care facility at Baylor College of Medicine according to the institu-
tional guidelines for the care and use of laboratory animals. For microarray
analysis, ovariectomized SRC-1/ and wild-type mice were injected with
vehicle (sesame oil) or P4 (1 mg/mouse in 100 L sesame oil) for 4 h (n  9
per genotype per treatment). For the steroid hormone treatment, ovari-
ectomized mice Mig-6f/f and Mig-6d/d mice were injected with 1 of the
following: vehicle (sesame oil), P4 (1 mg/mouse), E2 (0.1 g/mouse), P4 plus
E2 (n  5 per genotype per treatment). Hormone injections were repeated
every day to prevent the effect of hormone degradation by metabolism.
Mice were killed 6 h after the third injection. At the time of dissection,
uterine tissues were placed in the appropriate fixative or flash frozen and
stored at 80 °C. For the endometrial cancer study, ovariectomized Mig-
6d/d and Mig-6f/f mice received a pellet of either vehicle (beeswax), E2 (20
g/pellet), or E2  P4 (20 mg/pellet) at 8 weeks of age. Mice were killed at
5 months of age (n  10 per genotype per treatment).











Human Samples. Endometrial samples were obtained from 18 normally
cycling women, aged 18 –35, after written informed consent, under an
approved protocol by the Institutional Review Board at Baylor College of
Medicine. The endometrial sample was removed from the uterine fundus
with a Pipelle (circle R) biopsy catheter. Tissues were fixed in formalin and
embedded in paraffin for histological analysis or snap frozen on dry ice.
Histological samples were examined blindly by an independent patholo-
gist, and phases were assigned according to the Noyes criteria (46). Endo-
metrioid carcinoma samples were derived from hysterectomy surgical
specimens submitted to the Department of Pathology, M. D. Anderson
Cancer Center following the guidelines approved by the M. D. Anderson
Cancer Center Committee on Human Research and the Baylor College of
Medicine Committee on the Use of Human Subjects in Medical Research.
Classification was verified by light microscopic examination of hematoxylin
and eosin-stained slides by gynecologic pathologist Russell R. Broaddusd.
Normal endometrial samples were obtained from 5 cycling women (4
secretory and 1 atrophic stage) and endometrioid carcinoma samples were
obtained from 8 postmenopausal women and 2 cycling women. Endometri-
oid carcinoma samples from patients with a prior history of hormone use,
radiation treatment, or chemotherapy were not used for this study.
Microarray Analysis. Microarray analysis was performed by Affymetrix mu-
rine genome U74Av2 mouse oligonucleotide arrays (Affymetrix) as previ-
ously described (30). All experiments were repeated 3 times. Briefly, we
used DNA-Chip analyser dChip version 1.3 (47). We selected differentially
expressed genes within each time exposure using 2 sample comparisons
according to the following criteria: lower bound of 90% confidence inter-
val of fold change greater than 1.2 and absolute value of difference
between group means greater than 80. After excluding expressed se-
quence tags with no functional annotation, differentially expressed genes
were classified according to gene ontology function using Affymetrix
annotation, literature search in PubMed and GenMAPP (48).
Quantitative Real-Time RT-PCR. Expression levels of regulated genes were
validated by real time RT-PCR. Real-time probes and primers were pur-
chased from Applied Biosystems). All real-time RT-PCR was done using RNA
samples from 3 separate mice and mRNA quantities were normalized
against 18S RNA using ABI rRNA control reagents. Statistical analyses used
1-way ANOVA followed by Tukey’s post hoc multiple range test with the
Instat package from GraphPad.
Immunohistochemistry. Uterine sections from paraffin-embedded tissue were
cut at 5 m and mounted on silane-coated slides, deparaffinized, and rehydrated
in a graded alcohol series. Sections were preincubated with 10% normal serum in
PBS (pH 7.5) and then incubated with 1:1,000 anti-Mig-6 antibody (Sigma-
Aldrich) in10%normal seruminPBS (pH7.5).Onthefollowingday, sectionswere
washed in PBS and incubated with a secondary antibody (5 L/mL; Vector Labo-
ratories) for 1 h at room temperature. Immunoreactivity was detected using the
Vectastain Elite ABC kit (Vector Laboratories).
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